Pharmacological Treatment: Recent Developments
Currently, cholinesterase inhibitors (ChEI) represent the treatment of choice for Alzheimer’s Disease (AD) (Fig. 6.1). Following the 1980s introduction of a first generation of drugs such as physostigmine and tacrine, a second generation of more suitable compounds was developed in the 1990s. These drugs are clinically more efficacious and produce less severe side effects at effective doses.